A Phase 1 study of 177Lu-AB-3PRGD2 in Integrin αVβ3 positive tumors
Unknown Early Phase 1 NCT05013086
Study Description
A study to evaluate the safety and dosing of a new drug, 177Lu-AB-3PRGD2, for treating tumors with high levels of Integrin αVβ3
Study Details
- Registry ID:
- NCT05013086
- Conditions:
- Integrin αVβ3 Positive Tumors
- Phase:
- Early Phase 1
- Target Enrollment:
- 10 participants
- Start Date:
- Age Range:
- 18–80 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Peking Union Medical College Hospital
Beijing, Beijing, China
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.